Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves ’ orbitopathy?

ConclusionsPatients who deteriorate at 6 weeks after ivGCs are unlikely to benefit from continuing ivGCs. Patients unresponsive at 6 weeks still have a significant possibility of improvement later. Accordingly, they may continue ivGC treatment, or, alternatively, possibly stop ivGCs and be switched to a second-line treatment.
Source: Journal of Endocrinological Investigation - Category: Endocrinology Source Type: research